Group One Trading, L.P. Pro Qr Therapeutics N.V. Transaction History

Group One Trading, L.P.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.39 $9,240 - $13,384	-5,600 Reduced 57.79%	4,090 $6,000
Q1 2024 May 10, 2024	SELL	$1.89 - $2.85 $16,473 - $24,840	-8,716 Reduced 47.35%	9,690 $22,000
Q4 2023 Feb 14, 2024	BUY	$1.15 - $2.21 $9,936 - $19,094	8,640 Added 88.47%	18,406 $36,000
Q3 2023 Nov 09, 2023	BUY	$1.3 - $1.77 $7,636 - $10,396	5,874 Added 150.92%	9,766 $12,000
Q2 2023 Aug 09, 2023	BUY	$1.62 - $2.32 $6,305 - $9,029	3,892 New	3,892 $6,000
Q3 2022 Nov 09, 2022	SELL	$0.74 - $0.89 $13,357 - $16,064	-18,050 Reduced 30.5%	41,126 $31,000
Q2 2022 Aug 11, 2022	BUY	$0.56 - $1.0 $9,525 - $17,009	17,009 Added 40.34%	59,176 $46,000
Q1 2022 May 12, 2022	SELL	$0.9 - $8.39 $7,141 - $66,574	-7,935 Reduced 15.84%	42,167 $38,000
Q4 2021 Feb 11, 2022	BUY	$6.58 - $8.44 $324,203 - $415,847	49,271 Added 5929.12%	50,102 $401,000
Q3 2021 Nov 12, 2021	SELL	$5.16 - $8.47 $82,905 - $136,087	-16,067 Reduced 95.08%	831 $7,000
Q2 2021 Aug 10, 2021	BUY	$5.75 - $7.59 $97,163 - $128,255	16,898 New	16,898 $114,000
Q3 2020 Nov 12, 2020	SELL	$4.79 - $6.3 $27,303 - $35,910	-5,700 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$4.5 - $6.53 $360 - $522	80 Added 1.42%	5,700 $35,000
Q1 2020 May 13, 2020	SELL	$5.25 - $9.9 $137,991 - $260,211	-26,284 Reduced 82.38%	5,620 $31,000
Q4 2019 Feb 10, 2020	BUY	$5.84 - $10.51 $138,898 - $249,969	23,784 Added 292.91%	31,904 $316,000
Q3 2019 Nov 12, 2019	BUY	$5.76 - $9.44 $46,771 - $76,652	8,120 New	8,120 $47,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $199M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.